{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:41:32Z","timestamp":1787971292872,"version":"build-2784847793"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.dsx.2020.03.016","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T07:27:56Z","timestamp":1586417276000},"page":"283-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8374-4536","authenticated-orcid":false,"given":"Awadhesh Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2020.03.016_bib1","first-page":"12","article-title":"Time to use the p-word? Coronavirus enter dangerous new phase","volume":"579","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.dsx.2020.03.016_bib3","author":"Liu"},{"key":"10.1016\/j.dsx.2020.03.016_bib4","author":"Guan"},{"issue":"10223","key":"10.1016\/j.dsx.2020.03.016_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2020.03.016_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.dsx.2020.03.016_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.dsx.2020.03.016_bib8","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"9","author":"Zhou","year":"2020","journal-title":"Published Online March"},{"key":"10.1016\/j.dsx.2020.03.016_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.dsx.2020.03.016_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.dsx.2020.03.016_bib11","doi-asserted-by":"crossref","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et\u00a0al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001\/jamainternmed.2020.0994 (Accessed on March 27, 2020).","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"10.1016\/j.dsx.2020.03.016_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4683","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","author":"Onder","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.dsx.2020.03.016_bib13","doi-asserted-by":"crossref","unstructured":"Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et\u00a0al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. J Am Med Assoc. doi:10.1001\/jama.2020.3204. Published online March 3, 2020.","DOI":"10.1001\/jama.2020.3204"},{"key":"10.1016\/j.dsx.2020.03.016_bib14","doi-asserted-by":"crossref","unstructured":"Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et\u00a0al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. doi:10.1001\/jamacardio.2020.1017. Published online March 27, 2020.","DOI":"10.1001\/jamacardio.2020.1017"},{"key":"10.1016\/j.dsx.2020.03.016_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u00a0314 cases from the Chinese center for disease Control and prevention","author":"Wu","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.dsx.2020.03.016_bib16","doi-asserted-by":"crossref","unstructured":"Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. Comorbidities and multi-organ injuries in the treatment of COVID-19. Published Online March 9, 2020. HYPERLINK \"https:\/\/doi.org\/10.1016\/S0140-6736(20)30558-4\" (Accessed on March 27, 2020).","DOI":"10.1016\/S0140-6736(20)30558-4"},{"key":"10.1016\/j.dsx.2020.03.016_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.dsx.2020.03.016_bib18","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence?","volume":"24","author":"Patel","year":"2020","journal-title":"JAMA. Published online March"},{"key":"10.1016\/j.dsx.2020.03.016_bib19","article-title":"Antihypertensive drugs and risk of COVID-19?","author":"Tiganelli","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.dsx.2020.03.016_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30158-2","article-title":"Antihypertensive drugs and risk of COVID-19?","author":"Brown","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.dsx.2020.03.016_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30156-9","article-title":"Antihypertensive drugs and risk of COVID-19?","author":"Lo","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.dsx.2020.03.016_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","author":"Gurwitz","year":"2020","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.dsx.2020.03.016_bib23","first-page":"2020","article-title":"The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells","author":"Hoffmann","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.dsx.2020.03.016_bib24","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.dsx.2020.03.016_bib25","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","article-title":"Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2","volume":"24","author":"Li","year":"2005","journal-title":"EMBO J"},{"key":"10.1016\/j.dsx.2020.03.016_bib26","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1360\/04wc0153","article-title":"Reconstruction of the most recent common ancestor sequences of SARS-Cov S gene and detection of adaptive evolution in the spike protein","volume":"49","author":"Yuan","year":"2004","journal-title":"Chin Sci Bull"},{"issue":"7","key":"10.1016\/j.dsx.2020.03.016_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J\u00a0Virol"},{"issue":"1","key":"10.1016\/j.dsx.2020.03.016_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/22221751.2020.1713705","article-title":"Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus","volume":"9","author":"Kleine-Weber","year":"2020","journal-title":"Emerg Microb Infect"},{"issue":"1","key":"10.1016\/j.dsx.2020.03.016_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12944-018-0890-6","article-title":"Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China","volume":"17","author":"Pan","year":"2018","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.dsx.2020.03.016_bib30","article-title":"Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov","author":"Cai","year":"2020","journal-title":"Preprints"},{"issue":"3","key":"10.1016\/j.dsx.2020.03.016_bib31","first-page":"302","article-title":"Lessons from SARS: a new potential therapy for acute respiratory distress syndrome (ARDS) with angiotensin converting enzyme 2 (ACE2)","volume":"57","author":"Imai","year":"2008","journal-title":"Masui"},{"issue":"8","key":"10.1016\/j.dsx.2020.03.016_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A\u00a0crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.dsx.2020.03.016_bib33","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/CCM.0b013e3181c03009","article-title":"Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets","volume":"38","author":"Reml","year":"2010","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.dsx.2020.03.016_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A\u00a0pilot clinical trial of recombinant human angiotensin converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.dsx.2020.03.016_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.phrs.2017.06.005","article-title":"The vasoprotective axes of the renin-angiotensin system:physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases","volume":"125","author":"Li","year":"2017","journal-title":"Pharmacol Res"},{"issue":"20","key":"10.1016\/j.dsx.2020.03.016_bib36","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.dsx.2020.03.016_bib37","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1177\/1535370217718808","article-title":"Protective regulation of the ACE2\/ACE gene expression by estrogen in human atrial tissue from elderly men","volume":"242","author":"Bukowska","year":"2017","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.dsx.2020.03.016_bib38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.dsx.2020.03.016_bib39","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1038\/srep07027","article-title":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury","volume":"4","author":"Yang","year":"2014","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.dsx.2020.03.016_bib40","first-page":"419","article-title":"Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia","volume":"31","author":"Henry","year":"2018","journal-title":"SAVE Proc"},{"issue":"3","key":"10.1016\/j.dsx.2020.03.016_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00716-15","article-title":"Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers","volume":"6","author":"Fedson","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.dsx.2020.03.016_bib42","first-page":"1","article-title":"Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade","author":"Perico","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.dsx.2020.03.016_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.dsx.2020.03.016_bib44","doi-asserted-by":"crossref","first-page":"17996","DOI":"10.1074\/jbc.M311191200","article-title":"ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis","volume":"279","author":"Towler","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dsx.2020.03.016_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000504167","article-title":"Benefits and risks of continuing angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and mineralocorticoid receptor antagonists during hospitalizations for acute heart failure","volume":"10","author":"Oliveros","year":"2020","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.dsx.2020.03.016_bib46","doi-asserted-by":"crossref","unstructured":"Chen D, Li X, Song Q, Hu C, Su F, DaiJ, Ye Y, HuangJ, Zhang X. Hypokalemia and Clinical Implications in Patients with CoronavirusDisease 2019 (COVID-19). medRxiv preprint doi: https:\/\/doi.org\/10.1101\/2020.02.27.20028530.","DOI":"10.1101\/2020.02.27.20028530"},{"key":"10.1016\/j.dsx.2020.03.016_bib47","first-page":"E004","article-title":"Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV","volume":"48","author":"Peng","year":"2020","journal-title":"Zhonghua Xinxueguanbing Zazhi"},{"issue":"3","key":"10.1016\/j.dsx.2020.03.016_bib50","first-page":"219","article-title":"Inhibitors of RAS might Be a good choice for the therapy of COVID-19 pneumonia","volume":"43","author":"Sun","year":"2020","journal-title":"Zhonghua Jiehe He Huxi Zazhi"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120300564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120300564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:15:22Z","timestamp":1761729322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402120300564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1871402120300564"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2020.03.016","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2020.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}